FibroBiologics, Inc. Common Stock
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Peter O'Heeron
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 455 East Medical Center Boulevard Houston TX United States of America 77598
- IPO Date
- Feb 1, 2024
- CIK
- 0001958777
- Website
- fibrobiologics.com
- Similar Companies
- Business
- FibroBiologics, Inc. (Nasdaq: FBLG) operates as a clinical-stage biotechnology company focused on developing and commercializing fibroblast cell-based therapies and fibroblast-derived materials for the treatment and potential cure of chronic diseases. Founded in 2021 and headquartered in Houston, Texas, the company targets unmet medical needs in areas such as degenerative disc disease, multiple sclerosis, wound healing, psoriasis, orthopedics, cancer, and organ involution reversal including thymic and splenic applications. Its proprietary fibroblast platform leverages the regenerative and immune-modulating properties of fibroblasts, which the company demonstrates as more effective than stem cells in preclinical studies. Core products and product candidates include CybroCell, an allogeneic fibroblast therapy for degenerative disc disease and cartilage repair; CYMS101, an allogeneic fibroblast therapy for multiple sclerosis that has completed Phase 1 studies; CYWC628, an allogeneic fibroblast therapy for wound healing, including diabetic foot ulcers, with Phase 1/2 clinical trial approval received from the Human Research Ethics Committee in November 2025 and first-in-human trial initiation supported by recent financing; and CYPS317, an allogeneic fibroblast therapy for psoriasis, with IND-enabling studies underway. FibroBiologics holds over 150 U.S. and international patents issued or pending across these clinical pathways and serves patients globally through its clinical-stage pipeline. Recent developments include the complete payoff of outstanding debt in November 2025, comprising $15 million in convertible notes from a $25 million Standby Equity Purchase Agreement entered in December 2024 with YA II PN LTD., an affiliate of Yorkville Advisors; closings of registered direct offerings totaling $1.5 million in November 2025 and $4 million earlier that month, both priced at-the-market under Nasdaq rules; confirmation of manufacturing scalability for CybroCell using its CYWC628 master cell bank to support FDA IND amendment for Phase 1 trials in degenerative disc disease; reporting of third quarter 2025 financial results in October 2025; and presentations at major industry conferences including Bio-Europe 2025, ThinkEquity Conference, and Cell & Gene Meeting on the Mesa.
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
FibroBiologics CEO Issues Letter to Shareholders
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
FibroBiologics Compliant with All Nasdaq Listing Requirements
FibroBiologics Compliant with All Nasdaq Listing Requirements
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity